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Retinoic acid (RA) induced ifferentiation ofSH-SYSY neuroblastoma cells is associated with more than a tenfold induction of total Al&timer’s 
disease /IA4 amyloid protein precursor (APP) mRNA as analyzed by Northern blot hybridisation. Sl nuclease protection experiments reveal that 
the splicing pattern of these di&rentiated cells is altered in favor of APP,, mRNA, coding for the shortest amyloidogenic f?A4 amyloid precursor 
protein. Induction of differentiation of SH-SYN cells with NGF leads to a fivefold increase of total APP mRNA without change in the splicing 
pattern. This suggests that RA but not NGF induces factor(s) which are responsible for an APP hnRNA splicing favoring APP,, mRNA. 
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1. INTRODUCTION 
Alzheimer’s disease (AD) is an irreversible neuro- 
degenerative disorder of the human central nervous 
system [ 11. The neuronal dysfunction is correlated with 
massive deposition of fibrillar aggregates of the PA4 
protein in the brain [2,3]. The pathological /3A4 peptide 
consists of 42-43 residues and is synthesized as part of 
a larger N- and 0-glycosylated integral transmembrane 
precursor protein (APP for amyloid precursor protein) 
14-81. Proteolytic processing of these APP proteins in 
the Golgi apparatus leads to the secretion of the ex- 
tracellular part the APP protein isoforms [8]. Five dif- 
ferent transcripts of the single gene coding for the APP 
(PAD gene, 191) have been identified, which arise by 
alternative splicing [4-6,10-12,14,15]. The three major 
transcripts with sizes of 3.4 to 3.6 kb code for precursor 
proteins with 695,751 and 770 amino acids (APPags, 
APP7sr and APP770) [lO-121. The APP&APP770 pro- 
teins differ from APP69s by one or two additional do- 
mains of 56 or 56 and 19 amino acids [12]. Both do- 
mains are encoded by two adjacent exons on the PAD 
gene, namely exon 7 (168 bp) and exon 8 (57 bp) 
[ 12,131. The expression of the PAD gene is ubiquitous, 
being highest in brain and kidney [lo]. In situ hybridisa- 
tions as well as Northern blot analysis of brain and 
peripheral tissues demonstrated a higher expression of 
the two longer PAD transcripts in peripheral organs, 
whereas the short APPags mRNA is the dominant form 
in neuronal tissues [10,16]. In order to study the expres- 
sion of the PAD gene during neuronal differentiation 
we used the neuroblastoma cell line SH-SYSY, which 
can be induced to differentiate by nerve growth factor 
(NGF) and retinoic acid (RA) [ 17- 191. 
2. MATERIALS AND METHODS 
2.1. DNA constructs 
A 1.7 kb EcoRI fragment of a partial APP,ro cDNA clone, where 
the 5’EcoRI restriction site is introduced by the adaptor during con- 
struction of the cDNA library, and the 3’-EcoRI site is at position 
+ 2020 of APPrrc cDNA, was subcloned into the pUC19 polylinker, 
to give the recombinant plasmid ~2.21 [20,19]. Plasmid ~2.21 was 
digested with XhoI. resulting in a 826 bp fragment, spanning the KPI- 
and OX-2 domain from position + 320 to position + 1135, and was 
subcloned into the phage M13mp18 [22] which resulted in the recom- 
binant phage M8.11 (Fig. 1). The recombinant phage M15.36 was 
constructed by subcloning of a 682bp XhoI/SacI APP770 cDNA frag- 
ment from position + 1135 to position + 1817 into the phage 
M13mp19 (Fig. 1) [U]. The 1687bp DraIIVEcoRI cDNA fragment of 
the APP770 cDNA in ~2.21 was subcloned into the respective restric- 
tion sites of plasmid pSP65 (Promega) containing the 3048 bp 
SmaI/SmaI APP69s cDNA (pSP65/695), constituting plasmid 
pSP65/770. 
2.2. Cell culture methods 
Correspondence address: 0. Kiinig c/o K. Beyreuther, Center for 
Molecular Biology (ZMBH), University of Heidelberg, Im 
Neuenheimer Feld 282, D-6900 Heidelberg 1, FRG 
The subclone neuroblastoma cell line SH-SYSY was grown in equal 
parts of Minimum Essential Medium (MEM) with Earle’s Salts and L- 
glutamine and Ham’s F-12 supplemented with nonessential amino 
acids (Eagle’s formulation), 2.5 mg/ml fungizone, 50 mg/ml gen- 
tamycin (ah Gibco/BRL) and 10% heat-inactivated fetal calf serum 
(Boehringer Mannheim). Cells were seeded at a density below 2 x 10” 
cells/cm2 (low density) and passaged in log phase at a density of 1 to 
3 x lo* cells/cm2 (medium density). Differentiation was induced by 
culturing cells in medium supplemented with nerve growth factor (20 
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Fig. 1. (a) APPr70 cDNA in plasmid pSP65. The arrow indicates the translation start site, the coding region is shown as an open box. The KPI-exon 
is denoted as a black box, the OX-2-exon as a hatched box. TM stays for trammembrane coding region, the black bar below indicates the flA4 
coding portion of the APPrrc cDNA. (b) Phage M&l 1, and protected fragments after Sl digestion. The APPr70 cDNA is shown as an open bar. 
The black bars represent he KPI-exon, the hatched bar represents the OX-2-exon. (c) Phage M15.36, and protected fragments after Sl digestion. 
The APPT70 cDNA is shown as an open bar. 
ng/ml) (kindly provided by Dr. R. Heuman, 5000 fold concentrated 
stock solution in medium), or retinoic acid (10 @l, Sigma, WOO-fold 
concentrated stock solution in 10% ethanol) for the time indicated. 
Medium was exchanged every second day, except for the 2 day in- 
cubation times in which medium was changed once after 24 h. Cells 
were harvested after washing once in phosphate-buffered saline 
(Ca’ + /Mg2 + -free) with mechanical agitation. They were immediately 
used for RNA preparation or stored at - 80°C after shock freezing in 
liquid nitrogen. 
2.3. RNA preparation and Northern blot hybridiration 
Total RNA was extracted by the guanidinium isothiocyanate 
method [21,23] and 10 pg of total RNA was run in formaldehyde- 
agarose gels which were subsequently used for the Northern transfer 
TM [20.21,24]. Nytran filters (Schleicher and Schtlll) were used as the 
solid support. Prehybridisation and hybridisation of the filters were 
done in 5x SSPE, 5x Denhardt’s solution, 0.2% SDS, 50% for- 
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mamide and 100 Fg denatured calf thymus DNA overnight at 42°C. 
The 1182 bp BamHI/XhoI APPrrc cDNA restriction fragment was 
labelled by random priming (Boehringer Mannheim), and used at 
1 x 10’ cpm/ml for quantitation of total APP expression [25]. Con- 
trol hybridisations were done with the same filter after stripping off 
the APP probe and rehybridisation with the randomly primed 0.8kb 
XbuI/PstI fragment of the rat GAPDH cDNA (kindly provided by 
Francis Stewart pa]). The final stringent washes of the filter were 
done in 0.2 x SSC, 0.1% SDS at 65’C for 5 min. 
2.4. SI nuclease protection assay 
A uniformly labelled single-stranded DNA probe was synthesized 
by annealing 1 pmol of M 13 phage specific oligonucleotide primer to 
250 ng of single-stranded template DNA of MS.1 1 or M15.36 [27,28]. 
This primer was extended with 1 unit Klenow polymerase (Boehringer 
Mannheim) in the presence of 25mM dATP, dGTP, dTTP, 2 mM 
dCTP and 40 &i of (r-[32P]dCTP (3000 Ci/mmol, Amersham) for 15 
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minutes at 37OC. Extended products were digested with Sac1 (for 
MS. 11) or HindlIT (for M15.36) for 45 min, the labelled sh&e strand- 
ed DNA probes were purified on a 5% denaturing polyacrylamide get, 
cut out and electroeluted (Elutrap, Schleicher and Schtill). Excess 
a) 
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tot.APP 
APP&xi 
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409 
Fig. 2. (a) Sl nuclease protection assay with probe M8.11 and Ml536 
of RNA from SH-SYSY cells in the control and the NGF-induced dif- 
ferentiated state. The protected fragments of probe M8.11 (ApP7.10, 
APP7s1 and APF6s.s) and of probe M15.36 (tot. APP), are indicated. 
(Lane 1) molecular weight marker; (2 and 3) Sl probe MS.11 and 
M15.36, respectivefy; (4) control hybri~~tion of 20 pg yeast RNA to 
M8.11 and MIS.36 together in one sample; (5) protected fragments of 
ME. 11 in RNA of differentiated SH-SYSY cells after 8 days of NGF 
treatment; (6) protected fragment of M15.36 in RNA of differentiated 
SH-SYSY cells after 8 days NGF treatment; (8) protected fragments 
of probe M8.11 in RNA of SH-SYSY cells of the undifferentiated 
control state; (9) protected fragments of probe Ml536 in RNA of 
SH-SYSY cells of the undifferentiated control state. (b) Quantifica- 
tion of the Sl nuclease protection experiments of total APP mRNA 
i~duc~on after 8 days of NGF-treatment in differ~tiated SH-SYJY 
cells (n = 2). 
probe (50 000 cpm) was hybridised overnight o 5 or 10 fig of total 
RNA at 53°C in the case of probe M15.36 and at55OC in the case of 
probe MS.11 (75% formamide, 0.4 M NaCl. 20 mM TrislHCl pH 
7.4, and 1 mM EDTA). Sl nuclease digestion (Boehringer Mannheim, 
1200 U/sample) was performed for 2 h at 37°C (0.3 M NaCl, 3 mM 
ZnSO4,60 mM NaAc pH 4.5,0.5 @ denatured calf thymus DNA). 
The resulting products phenol/CHCl3-ex~act~, ethanol precipitated 
and resolved on a 5% denaturing sequencing el. Autoradiography 
was performed using Kodak X-OMATTM AR films, and appropriate- 
ly exposed X-ray films with signals in the linear responsive range were 
used for densitometry on a Hirschmann elscript 400 densitometer. 
3. RESULTS AND DISCUSSION 
After 8 days in cuiture in the presence of NGF (20 
nglml) the majority of SH-SYSY cells extend neurites, 
cease multiplying, aggregate, and have electrically ex- 
citable membranes [28]. They resemble closely the 
phenotype of a primary culture of sympathetic ganglia 
after treatment with NGF. Total RNA was prepared 
and subsequently used for Sl nuclease analysis with 
123456789 
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Fig. 3. (a) Northern hybri~tion analysis of RNA from SH-SYSY 
cells treated with RA to induce differentiation. The signal of the APP 
mRNA (APP) runs at approximately 3.6kb. (1) RNA from SH-SYSY 1 
cells in the low density control state, (2-9) RNA from SH-SYSY cells 
treated with RA for the times indicated. (b) Quantification of the in- 
duction of total APP mRNA (total APP) during ~fferentiation with 
RA. 
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probe MS.11 as well as with probe M15.36. We observ- It has been reported that retinoic acid (RA) is a po- 
ed a fivefold higher expression of the PAD gene in the tent inducer of differentiation in neuroblastoma cells 
differentiated cells compared to control cells (Fig. 2a, [3 11. When SH-SYSY cells were cultured in the presence 
lanes 6 and 9; Fig. 2a, lanes 5 and 8, Fig. 2b) which is of RA, the majority of the cells developed the 
in agreement with the developing hamster brain [30]. characteristic phenotype of differentiated neurons after 
Different exposure times to NGF did not result in a four to five days (Fig. 5a and b). Between days 6 and 12 
stronger response of the PAD gene to this agent (data the typical morphology of differentiated neuro- 
not shown). In undifferentiated as well as NGF induced blastoma cells could be maintained. The RA-induced 
differentiated SH-SYSY CdS the APP695 kInSCript ac- differentiated SH-SYSY cells showed consistently a 
counts for about 49070, the APP751 transcript for about more slender and longer bipolar morphology than cells 
41070, and the APP770 transcript for about 10% of total which were differentiated through NGF. A less than 
APP mRNA. twofold increase in total APP mRNA is seen during the 
1 234567 
1 
APPe 
* 
APp751- : I !
8 9 10 11 12 
Cc 5’ 30’ 2h 8h 2d 4d 8d 23d 
Fig. 4. (a) Sl nuclease protection assay with probe ME. 11 of RNA from SH-SYSY cells treated for various times with RA to induce differentiation. 
(1) molecular weight marker in bases, (2,3) probe ME.1 1 and the control hybridisation to 10 c(8 yeast tRNA; (5-12) the protected fragments in RNA 
of SH-SYSY cells treated for various times with RA in comparison to the control state of low density cells (4) (b) Quantification of the Sl nuclease 
protection experiments on the RNA of SH-SYSY cells treated for various times with RA to induce differentiation (n = 3). 
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first 8 hours of RA administration (Fig. 3a, lanes 2-5; 
Fig. 3b). The marked increase in PAD gene expression 
peaks at day 4 in culture with RA with an induction fac- 
tor of 10.2. APP mRNA remains elevated through day 
23, the longest timepoint tested, with a factor of 4.3, 
compared to control cells (Fig. 3). The sizes of the PAD 
transcripts were in the range of 3.6 kb. 
The ratios of the different PAD transcripts in the 
same RNA preparation, measured with probe MS. 11 in 
a Sl nuclease protection assay, reveals a significant 
shift in the splicing pattern within a slightly different 
time frame as observed for the increase of total APP 
mRNA. Whereas in control cells grown at a low density 
the relative amount of APPQx transcript is 54%) in cells 
which were treated with RA over a period of 8 days, the 
APP695 transcript makes up 70% of total PAD 
transcripts (Fig. 4a, lanes 4 and 11, Fig. 4b). In contrast 
APP770 mRNA is reduced to 3.5% and APP75r mRNA 
to 26.5% of total APP mRNA compared to 37.5% of 
APP75r mRNA and 8.5% of APPuo mRNA in undif- 
ferentiated cells grown at low density (Fig. 4a, lanes 4 
and 11, Fig. 4b). This change of the splicing pattern is 
only seen after an initial maximal increase of total APP 
mRNA at day 4 and is associated with an increase of 
total PAD expression. The more immediate response of 
the total PAD gene expression by a factor of about 2, 
which peaks at 2 h after RA-administration, does not 
lead to a significant change in the splicing pattern (Fig. 
4a, lanes 4-7, Fig. 4b). 
The total increase of APP695 mRNA is tenfold at 
days 4 and 8. The APP75r mRNA is increased by a fac- 
tor of 9.5 at day 4, and 6 at day 8, and the APP~~o 
mRNA by a factor of 12 at day 4 and only 3.4 at day 8. 
These data demonstrate an alternative splicing pattern 
of the APP hnRNA in differentiated SH-SYSY cells, in- 
duced by RA, in favor of the APP695 mRNA. 
The neurotrophic factor NGF is known to be impor- 
tant in maintenance and survival of sympathetic and 
sensory neurons of the peripheral nervous system [32]. 
It has been shown that NGF stimulates the outgrowth 
of sympathetic neurons into the central nervous system 
[33]. Retinoic acid however is a potent morphogen 
which plays an important role in the development of the 
CNS of vertebrates [34]. RA has been shown to be in- 
volved in the establishment of an anterior-posterior axis 
in the CNS and during the limb development in 
vertebrates [35,36]. It binds to nuclear receptors 
(hRAR) which are ligand-dependent transcription fac- 
tors, thereby activating the DNA binding capability of 
these receptors and regulating gene expression through 
responsive elements in the promoter region [37-401. 
A possible explanation for the differences observed 
in the APP expression in RA-induced differentiated 
cells could be a regulation of genes by RA involved in 
the expression of specific splicing factors responsible 
for the alternative splicing of the PAD gene. These RA- 
target genes would not be affected by NGF, thus not in- 
volving a change in the splicing program in these cells. 
1 Fig. 5.(a) Effect of RA on the morphology of SH-SYSY cells (phase contrast). (a) Cells were seeded at a density below 2 x 10’ cells/cm2 and grown 
for 4 days. Medium was changed after the second day. (b) Early log phase SH-SYSY cells were treated with RA (10 CM) for 8 days. Medium was 
changed every second day. 
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